학술논문
Biomarkers predictive of response to pembrolizumab in head and neck cancer.
Document Type
article
Author
Pfister, David; Haddad, Robert; Worden, Francis; Weiss, Jared; Mehra, Ranee; Chow, Laura; Liu, Stephen; Kang, Hyunseok; Saba, Nabil; Wirth, Lori; Sukari, Ammar; Massarelli, Erminia; Ayers, Mark; Albright, Andrew; Webber, Andrea; Mogg, Robin; Lunceford, Jared; Huang, Lingkang; Cristescu, Razvan; Cheng, Jonathan; Seiwert, Tanguy; Bauml, Joshua
Source
Cancer Medicine. 12(6)
Subject
Language
Abstract
BACKGROUND: We performed an integrated biomarker evaluation in pembrolizumab-treated patients with R/M HNSCC enrolled in KEYNOTE-012 or KEYNOTE-055. The relationship between biomarkers and HPV status was explored. METHODS: We evaluated PD-L1 (combined positive score [CPS]), TMB, T-cell-inflamed gene expression profile (Tcellinf GEP), and HPV status. Associations between biomarkers were evaluated by logistic regression (ORR) and Cox regression (PFS, OS). RESULTS: Two hundred and fifty-seven patients (KEYNOTE-012, n = 106; KEYNOTE-055, n = 151) had TMB data available; of these, 254 had PD-L1 and 236 had Tcellinf GEP. TMB, PD-L1, and Tcellinf GEP were each significantly associated with ORR (p